SP323EFFECTS OF RVX-208, A FIRST IN CLASS EPIGENETIC BET INHIBITOR, ON KEY RENAL PARAMETERS IN SUBJECTS WITH A HISTORY OF CVD, AND CHRONIC KIDNEY DISEASE (CKD); A POST-HOC ANALYSIS OF PATIENTS FROM THE ASSERT, SUSTAIN AND ASSURE CLINICAL TRIALS

Skip to main content

Open Access Publications from the University of California

SP323EFFECTS OF RVX-208, A FIRST IN CLASS EPIGENETIC BET INHIBITOR, ON KEY RENAL PARAMETERS IN SUBJECTS WITH A HISTORY OF CVD, AND CHRONIC KIDNEY DISEASE (CKD); A POST-HOC ANALYSIS OF PATIENTS FROM THE ASSERT, SUSTAIN AND ASSURE CLINICAL TRIALS

2015

Published Web Location

https://doi.org/10.1093/ndt/gfv191.43

Main Content

For improved accessibility of PDF content, download the file to your device.